Phase II Study of the combination of Elotuzumab with Lenalidomide as Maintenance Therapy post Autologous Stem Cell Transplant in Patients with Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Elotuzumab (Primary) ; Lenalidomide (Primary) ; Dexamethasone; Diphenhydramine; Famotidine
- Indications Multiple myeloma
- Focus Therapeutic Use
- 26 May 2017 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
- 26 May 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 15 Apr 2016 Change in Elotuzumab dosing: earlier it was given on day 1 and 15 after the 2nd cycle, now it is given only on day 1 and planned Patient number increased from 48 to 100.